A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer

Vladimir Avkshtol
Yanqun Dong
Shelly B Hayes
Mark A Hallman
Robert A Price
Mark L Sobczak
Eric M Horwitz*
Nicholas G Zaorsky*

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

*These authors contributed equally to this work

Abstract: Prostate cancer is the most prevalent cancer diagnosed in men in the United States besides skin cancer. Stereotactic body radiation therapy (SBRT; 6–15 Gy per fraction, up to 45 minutes per fraction, delivered in five fractions or less, over the course of approximately 2 weeks) is emerging as a popular treatment option for prostate cancer. The American Society for Radiation Oncology now recognizes SBRT for select low- and intermediate-risk prostate cancer patients. SBRT grew from the notion that high doses of radiation typical of brachytherapy could be delivered noninvasively using modern external-beam radiation therapy planning and delivery methods. SBRT is most commonly delivered using either a traditional gantry-mounted linear accelerator or a robotic arm-mounted linear accelerator. In this systematic review article, we compare and contrast the current clinical evidence supporting a gantry vs robotic arm SBRT for prostate cancer. The data for SBRT show encouraging and comparable results in terms of freedom from biochemical failure (>90% for low and intermediate risk at 5–7 years) and acute and late toxicity (<6% grade 3–4 late toxicities). Other outcomes (eg, overall and cancer-specific mortality) cannot be compared, given the indolent course of low-risk prostate cancer. At this time, neither SBRT device is recommended over the other for all patients; however, gantry-based SBRT machines have the abilities of treating larger volumes with conventional fractionation, shorter treatment time per fraction (~15 minutes for gantry vs ~45 minutes for robotic arm), and the ability to achieve better plans among obese patients (since they are able to use energies >6 MV). Finally, SBRT (particularly on a gantry) may also be more cost-effective than conventionally fractionated external-beam radiation therapy. Randomized controlled trials of SBRT using both technologies are underway.

Keywords: prostate cancer, stereotactic body radiation therapy, technology, quality of life

Introduction
Prostate cancer is the most prevalent cancer diagnosed in men in the United States aside from skin cancer.1 Radiation options for prostate cancer include external-beam radiation therapy (EBRT) and brachytherapy (BT).2 Most men who undergo EBRT are treated with conventionally fractionated RT (CFRT; 1.8–2 Gy per fraction, 15 minutes per day, 5 days per week, for approximately 8 weeks, to a total dose of 76–80 Gy).

Due to the prolonged treatment course, short-duration therapies that provide comparable disease-control rates are drawing interest as alternatives to CFRT. Advances in technology have allowed for the safe delivery of higher doses per fraction, ie, hypofractionated RT (HFRT; 2.1–3.5 Gy per fraction, 15 minutes per day, 5 days per week, for approximately 4 weeks)3 and stereotactic body RT (SBRT, for five fractions of...
Advantages and disadvantages of various forms of RT for prostate cancer

<table>
<thead>
<tr>
<th>Modality</th>
<th>Machines for RT delivery</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFRT, 1.8–2 Gy per fraction, 5 days/week, ~8 weeks</td>
<td>Gantry LINAC, Helical tomotherapy</td>
<td>Radiosensitization of tumor cells through redistribution, reoxygenation, and repair of sublethal damage in normal tissue Improves biochemical control in studies</td>
<td>Up to 45 treatments over 9 weeks QOL: early rectal toxicity commonly seen; late rectal, urinary, sexual toxicity sometimes seen Higher cost secondary to protracted treatment delivery, which builds cost with the delivery of each fraction Initial prospective trials inconclusive regarding efficacy QOL outcomes: inconclusive, with some studies showing increased toxicity and others showing decreased toxicity compared to CFRT Modern prospective trials ongoing</td>
</tr>
<tr>
<td>HFRT, 2.1–3.5 Gy per fraction, 5 days/week, ~4 weeks</td>
<td>Gantry LINAC, Helical tomotherapy</td>
<td>Potentially increased radiobiological efficacy and decreased normal tissue toxicity</td>
<td></td>
</tr>
<tr>
<td>SBRT, 6–15 Gy per fraction, five fractions, over ~2 weeks</td>
<td>Gantry LINAC, Robotic arm LINAC, Helical tomotherapy</td>
<td>Shorter treatment-delivery time compared to CFRT Lower cost compared to CFRT</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CFRT, conventionally fractionated radiation therapy; HFRT, hypofractionated radiation therapy; LINAC, linear accelerator; SBRT, stereotactic body radiation therapy; QOL, quality of life; RT, radiation therapy.

6–15 Gy per fraction lasting up to 45 minutes per day, one to five treatments, over the course of approximately 2 weeks. For reference, the relative benefits and risks of EBRT types are listed in Table 1.

SBRT is commonly delivered using a traditional linear accelerator (LINAC; ie, with a gantry) or a robotic arm (ie, CyberKnife; Accuray Incorporated, Sunnyvale, CA, USA). We provide a comparative review of the current clinical evidence behind gantry vs robotic arm SBRT for prostate cancer. First, we review the radiobiology, physics, patient perspective, and resource-allocation considerations behind each technology. Second, we compare published disease-control outcomes and toxicities. Finally, we discuss the future of these technologies, as well as clinical trials on the horizon. For reference, the dose fractionations and sample treatment plans for CFRT, gantry SBRT, robotic arm SBRT, and high-dose-rate BT (HDR-BT) are illustrated in Figure 1.

Materials and methods

We defined the inclusion criteria for this literature search using the PICOS (population, intervention, control, outcome, study design) approach (Table S1). We conducted a systematic search using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) literature-selection process (Figure S1). We searched the published English-language medical literature from 1970 to 2015 in Medline and PubMed using the terms “prostate cancer”, “stereotactic body radiation therapy”, OR “CyberKnife”. We searched through reference lists of identified papers for further leads. Limitations of the PICOS/PRISMA method include the lack of individual patient data, the limited number of studies published, the relative differences in patient staging (eg, low-, intermediate-, and high-risk groups), the multiple methods of RT delivery (ie, gantry vs robotic arm and also differences in image guidance), differences in follow-up time (eg, 2–7 years median), and differences in reporting on outcomes (eg, biochemical failure [BF] differences at different time points).

Notably, other technologies may be used to deliver SBRT, including tomotherapy and protons. However, there were no articles identified in our PICOS/PRISMA selection criteria where these devices were solely used to deliver SBRT for prostate cancer. Instead, some patients within other studies may have been treated with the technologies. Therefore, we were unable to evaluate them fairly versus more conventional devices (ie, gantry-based LINACs with photons and robotic arm photons [ie, CyberKnife]), and we excluded them from the analysis. We mention that these devices may be used to deliver SBRT in the Discussion section of the paper, and how they may be used in clinical trials evaluating SBRT.

After identifying full-text articles, we excluded articles focusing on HDR-BT, treatment with tomotherapy SBRT, SBRT as a boost, SBRT as adjuvant treatment, and nonlocalized prostate cancer. We then further excluded articles that did not have disease-control data or had less than a 30-month median follow-up. We included studies that gave androgen-deprivation therapy. The search and screening yielded three gantry-SBRT publications and eleven robotic arm-SBRT publications (Table 2). Patients were organized by risk-group classification from the studies, namely, the National Comprehensive Cancer Network (NCCN) criteria, the preferred staging system.

There were more studies identified where patients were treated with robotic arm LINAC SBRT. Additionally, there were more patients with high-risk disease who were treated on a robotic arm LINAC. This difference comes principally from the history of the evolution of the technologies, and
the subsequent differences in how the technologies were integrated among different hospitals. When the robotic arm LINAC was first introduced in 2001, it was purported to be a “virtual HDR-BT”: it was designed to deliver the doses of HDR-BT noninvasively. Following this promotion, most centers delivering SBRT for prostate cancer started to use the robotic arm LINAC. Nonetheless, gantry-based LINACs may also be used for prostate SBRT. In the 15 years that followed since the inception of the robotic arm LINAC, more patients were treated on the robotic arm LINAC, which accounts for the larger number of patients and more patient heterogeneity among the gantry-based LINAC studies.

Notably, high-risk patients, either with high-grade or bulky (ie, T3–T4 disease), were not typically treated with SBRT. Nonetheless, these patients may still benefit from the local tumor control of SBRT with either technology. For patients with high-grade (ie, Gleason 8+) tumors, the current focus is the use of systemic therapy (eg, with novel antiandrogens). For patients with bulky disease, SBRT is avoided, given the concerns for increased toxicity.
Table 2 SBRT for prostate cancer with at least 30-month follow-up

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Patients (n)</th>
<th>Risk group</th>
<th>Median FU (months)</th>
<th>Total dose (Gy)</th>
<th>Total fractions</th>
<th>Gy per fraction</th>
<th>BED (Gy) at a/β of 1.5 (for TC)</th>
<th>BED (Gy) at a/β of 3.0 (for LT)</th>
<th>Actuarial FFBF*</th>
<th>RTOG/CTCAE late toxicity grade ≥2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gantry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madsen et al10</td>
<td>II</td>
<td>40</td>
<td>L, I, H</td>
<td>41</td>
<td>33.5</td>
<td>5</td>
<td>6.7</td>
<td>156</td>
<td>82</td>
<td>2 years: 90%</td>
<td>20, 7.5</td>
</tr>
<tr>
<td>Loblaw et al12</td>
<td>II</td>
<td>84</td>
<td>L, I, H</td>
<td>55</td>
<td>35</td>
<td>5</td>
<td>7</td>
<td>170</td>
<td>89</td>
<td>5 years: 98%</td>
<td>5, 8</td>
</tr>
<tr>
<td>Mantz10</td>
<td>II</td>
<td>102</td>
<td>L</td>
<td>60</td>
<td>40</td>
<td>5</td>
<td>8</td>
<td>221</td>
<td>115</td>
<td>5 years: 100%</td>
<td>NR, NR</td>
</tr>
<tr>
<td><strong>Robotic arm</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friedland et al11</td>
<td>NA</td>
<td>112</td>
<td>L, I, H</td>
<td>48</td>
<td>35</td>
<td>5</td>
<td>7</td>
<td>170</td>
<td>89</td>
<td>3 years: 97%</td>
<td>NR, NR</td>
</tr>
<tr>
<td>Katz et al12,13</td>
<td>II</td>
<td>50</td>
<td>L, I, H</td>
<td>40</td>
<td>35</td>
<td>5</td>
<td>7</td>
<td>170</td>
<td>89</td>
<td>4 years: 98.5%</td>
<td>7.8, 4.2</td>
</tr>
<tr>
<td>Kang et al14</td>
<td>NA</td>
<td>5</td>
<td>L, I, H</td>
<td>40</td>
<td>32</td>
<td>4</td>
<td>8</td>
<td>179</td>
<td>93</td>
<td>5 years: 100%</td>
<td>6.8, 11</td>
</tr>
<tr>
<td>McBride et al15</td>
<td>I</td>
<td>10</td>
<td>L</td>
<td>45</td>
<td>37.5</td>
<td>5</td>
<td>7.3</td>
<td>195</td>
<td>101</td>
<td>100%, 90.8%</td>
<td>3 years: 98% 19.2, 12</td>
</tr>
<tr>
<td>King et al16</td>
<td>II</td>
<td>16</td>
<td>L</td>
<td>32</td>
<td>36.3</td>
<td>5</td>
<td>7.3</td>
<td>182</td>
<td>95</td>
<td>4 years: 94%</td>
<td>8.7, 2</td>
</tr>
<tr>
<td>King et al17,18</td>
<td>II</td>
<td>1,100</td>
<td>L, I, H</td>
<td>36</td>
<td>35-40</td>
<td>4-5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>5 years: 93%</td>
<td>(95%, 84%, 81%)</td>
</tr>
<tr>
<td>Bolzico et al19</td>
<td>II</td>
<td>100</td>
<td>L, I, H</td>
<td>36</td>
<td>35</td>
<td>5</td>
<td>7</td>
<td>170</td>
<td>89</td>
<td>3 years: 94.4%</td>
<td>4, 1</td>
</tr>
<tr>
<td>Katz and Ret</td>
<td>154</td>
<td>L, I, H</td>
<td>72</td>
<td>36.3</td>
<td>7.3</td>
<td>182</td>
<td>95</td>
<td>5 years: 93%</td>
<td>NR, NR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang20,21,22</td>
<td>Ret</td>
<td>158</td>
<td>L, I, H</td>
<td>72</td>
<td>36.3</td>
<td>7.3</td>
<td>182</td>
<td>95</td>
<td>5 years: 93%</td>
<td>10.9, 4.1</td>
<td></td>
</tr>
<tr>
<td>Fuller et al23</td>
<td>II</td>
<td>53</td>
<td>L, I, H</td>
<td>60</td>
<td>38</td>
<td>4</td>
<td>9.5</td>
<td>250</td>
<td>130</td>
<td>5 years: 100%</td>
<td>15, 1</td>
</tr>
<tr>
<td>Lee et al23</td>
<td>Ret</td>
<td>29</td>
<td>L, I, H</td>
<td>41</td>
<td>35-37.5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>4 years: 92.8%</td>
<td>6, 0</td>
</tr>
<tr>
<td>Bernetich et al24</td>
<td>Ret</td>
<td>107</td>
<td>L, I, H</td>
<td>38</td>
<td>35</td>
<td>5</td>
<td>7</td>
<td>170</td>
<td>89</td>
<td>5 years: 100%</td>
<td>16, 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30</td>
<td></td>
<td>37.5</td>
<td>7</td>
<td>7.5</td>
<td>195</td>
<td>101</td>
<td>94.2%, 83.9%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ‘Listed as overall FFBF or for low-, intermediate-, and high-risk groups; † least some data published previously. ‡ For actuarial FFBF, low, intermediate, and high risk group data shown as separate values if available. The (a/β) ratio provides an estimate of the radiosensitivity of cells.

Abbreviations: BED, biological equivalent dose; CTCAE, Common Terminology Criteria for Adverse Events; FFBF, freedom from biochemical failure; FU, follow-up; GI, gastrointestinal; GU, genitourinary; H, high; I, intermediate; L, low; LT, late toxicity; NA, not applicable; NR, not reported; Ret, retrospective; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy; TC, tumor control.

Theoretical benefits of robotic arm vs gantry SBRT

Radiobiology

Fractionation has several theoretical radiobiological advantages, including repair, redistribution, and reoxygenation. The basis of fractionation is that dividing a dose into several fractions increases damage to the cancer cells because of reoxygenation of hypoxic tumors and redistribution of cells into radiosensitive phases of the cycle, while at the same time allowing the normal tissues to repair sublethal damage between fractions. However, the benefits of a higher dose are countered by the increased toxicity to the surrounding normal tissue. The α/β ratio is used to approximate the effects of radiation on different tissues and to compare various dose/fractionation schemes. The α/β ratio is thought to be >10 Gy for early responding tissues, including skin, mucosa, and most malignant tumors. The α/β ratio is thought to be around 3–5 Gy for late-responding tissues, including connective tissues and muscles. Clinical radiobiological models suggest that prostate cancer has a low α/β ratio (~1.5), unlike most other malignancies. The low α/β ratio means that prostate cancer cells should be more sensitive to radiation when the dose is delivered in large fraction sizes. Hypothetically, SBRT should increase tumor-cell death and decrease radiation-related toxicity compared to CFRT by improving the therapeutic ratio. Typically, as the total RT dose delivered increases, the number of surviving cells decreases. However, the benefits of a higher dose are countered by the increased toxicity to the surrounding normal tissue. The α/β ratio is used to approximate the effects of radiation on different tissues and to compare various dose/fractionation schemes. The α/β ratio is thought to be >10 Gy for early responding tissues, including skin, mucosa, and most malignant tumors. The α/β ratio is thought to be around 3–5 Gy for late-responding tissues, including connective tissues and muscles. Clinical radiobiological models suggest that prostate cancer has a low α/β ratio (~1.5), unlike most other malignancies. The low α/β ratio means that prostate cancer cells should be more sensitive to radiation when the dose is delivered in large fraction sizes.
SBRT for prostate cancer: robotic arm vs gantry equivalent dose (BED) formula explains the sensitivity to the larger fraction size:

$$\text{BED} = nd \left[ 1 + d/\left(\alpha/\beta\right) \right]$$ (1)

In this formula, $n$ is the number of radiation fractions and $d$ is dose size per fraction.

If the $\alpha/\beta$ ratio for the tumor is lower than that for the surrounding tissues, as hypothesized for prostate cancer, increasing the dose per fraction increases the BED more for the tumor than for the normal tissues. If the $\alpha/\beta$ ratio for the tumor is lower than that for the normal tissues, increasing the dose per fraction would increase the BED for the tumor more than the BED for the normal tissues, and the therapeutic ratio would be improved.

Abbreviations: BED, biologically equivalent dose; CFRT, conventionally fractionated radiation therapy; SBRT, stereotactic body radiation therapy; RTOG, Radiation Therapy Oncology Group; U Michigan, University of Michigan; UTSW, University of Texas Southwestern Medical Center.

Figure 2 Biologically equivalent dose vs $\alpha/\beta$ ratio for various EBRT-fractionation regimens.

Notes: The BEDs for several clinical trials mentioned (solid red line) compared to the regimen of dose-escalated CFRT monotherapy (dashed black line). SBRT (vs CFRT) allows for a higher BED at $\alpha/\beta$ of 1.5 (for prostate cancer) than at $\alpha/\beta$ of 3 (for late toxicity), thereby increasing the therapeutic ratio. The $\alpha/\beta$ ratio provides an estimate of the radiosensitivity of cells. Radiobiological models based on clinical data suggest that prostate cancer has a low $\alpha/\beta$ ratio of ~1.5 Gy, implying that prostate cancer cells are more sensitive to doses delivered in larger fraction size. This value is lower than the 3 Gy estimated for late-responding tissues (eg, bladder/rectal mucosa, muscles). If the $\alpha/\beta$ ratio for the tumor is lower than that for the normal tissues, increasing the dose per fraction would increase the BED for the tumor more than the BED for the normal tissues, and the therapeutic ratio would be improved.

SBRT has become increasingly popular since the 2000s, and since its inception, it has been marketed as a noninvasive alternative to HDR-BT.4,29,47 EBRT and BT have different
dosimetric characteristics in terms of conformity and heterogeneity, as well as normal-tissue sparing (shown in Figure 1). For example, for BT, there is greater dose heterogeneity, with higher dose regions near the catheters, whereas with EBRT, the dose is generally more homogeneous. There is currently no evidence that gantry or robotic arm SBRT provides a more favorable BED for the tumor while lowering the BED to the normal tissues. As a result, both delivery systems should benefit similarly from this radiobiological therapeutic advantage.

**Physics**

Both robotic arm and gantry SBRT employ cutting-edge image-guidance systems, which allow for the detection and correction of target motion and systematic and random errors during treatment. Robotic arm SBRT utilizes gold fiducial markers for image guidance, which can limit its use in people who are unwilling to undergo a procedure to place the fiducials. Gantry SBRT can utilize severe different imaging-guidance modalities, including cone-beam computed tomography (CT), radiofrequency transponders (eg, Calypso®), CT on rails, or gold fiducial markers.

During robotic arm SBRT, the gold fiducial markers are tracked by a set of orthogonal images taken every 15–30 seconds (or less often, depending upon the amount of target motion), and the robotic arm position adjusts accordingly. Meanwhile, gantry-based SBRT usually relies on a single snapshot assessment of the prostate position at the beginning of the fraction using cone-beam CT or implanted fiducial markers. There is no continuous imaging during treatment delivery to assess intrafraction prostate motion, leading to greater localization uncertainty during the treatment. This uncertainty led to the development of radiofrequency-emitting transponders (ie, Calypso beacons), which provide real-time interfraction and intrafraction assessment of prostate motion. If radiofrequency beacons are used for image guidance, the treatment can be paused and the patient repositioned to ensure correct localization within the treatment field. The radiofrequency transponders do come at a monetary cost and require the magnetic resonance imaging simulation to be performed prior to their placement to prevent imaging artifacts from the transponders.

Depending on the image-guided RT method employed, protocol used, and the treating physician’s confidence, different planning target volume (PTV) margins are used during prostate SBRT, which could affect the toxicity profile. Almost all SBRT robotic arm studies used a protocol that called for an expansion margin of 5 mm in all directions except for 0 mm posteriorly, whereas with EBRT the dose is generally more homogeneous. There is currently no evidence that gantry or robotic arm SBRT provides a more favorable BED for the tumor while lowering the BED to the normal tissues. As a result, both delivery systems should benefit similarly from this radiobiological therapeutic advantage.

**Patient perspective**

The treatment course of SBRT, usually 6 weeks shorter than CFRT, would be more accepted by patients because the length of treatment is the most frequently patient-cited drawback of CFRT. Along with the inconvenience, there are also out-of-pocket costs that the patient must incur with the longer conventional fractionation. Loblaw et al estimated that their five-fraction treatment course saved their patients an average CAD $1,928 (around USD $1,522 at the time of writing) for travel, parking, accommodation, and time off work compared to a standard 39-fraction course.

Although both gantry and robotic arm SBRT offer the benefit of a shorter treatment course, gantry SBRT has the advantage of shorter time to deliver each fraction. A typical gantry-arm SBRT fraction for prostate cancer lasts approximately 15 minutes. The length of treatment is only several minutes longer than CFRT despite the increase in dose per fraction, because gantry delivery time is largely limited by the maximum speed of the multileaf collimator leaves rather than the dose rate. A typical robotic arm treatment, at around 45 minutes, is three times as long. Lying still for such a prolonged period of time can cause significant discomfort for some patients.

**Resource allocation**

SBRT can potentially reduce costs compared to CFRT. Calculation models have shown that wage costs outweigh the cost of machines because of the labor-intensive nature of RT planning and delivery. Although the SBRT treatment-planning cost is high, this cost is only incurred once, at the beginning of treatment. On the other hand, the delivery cost, ie, the cost to run the treatment machine, increases with the number of fractions. The significant reduction in treatment course afforded by SBRT results in overall savings. The
mean cost of conventional intensity-modulated RT (IMRT), $29,356, is higher than the estimated cost of robotic arm SBRT, between $19,275 and $24,873. Parthan et al compared the cost-effectiveness of IMRT with SBRT and proton-beam therapy using the Markov model, assuming equal long-term efficacy. SBRT was more cost-effective in 75% and 94% of simulations compared with IMRT and proton-beam therapy, respectively.

The Centers for Medicare & Medicaid Services also used a Markov model to compare cost effectiveness, but biased its study against SBRT by assuming increased late toxicity from hypofractionation. The study used the 2012 Medicare payment schedule for hospital-based practice to determine the baseline cost of each treatment. Medicare estimated the cost of robotic SBRT and nonrobotic SBRT to be $19,275.41 and $10,108.93, respectively. The incremental cost-effectiveness ratio for IMRT over nonrobotic SBRT was $591,100 per quality-adjusted life year. The incremental cost-effectiveness ratio for IMRT over robotic arm SBRT was $591,100 per quality-adjusted life year, despite almost twice the cost of nonrobotic SBRT. The difference between gantry and robotic arm SBRT was elucidated by Sharieff et al. They calculated the cost of robotic arm SBRT to be $6,333 per patient and gantry-based SBRT to be $4,368 per patient.

In practice, a robotic arm SBRT system is typically only used to deliver SBRT, due to its long treatment times, which limit its usefulness for more protracted treatment regimens. Newer multileaf collimator-equipped versions offer the ability to treat larger targets, with the potential to decrease treatment times. A gantry-SBRT platform can be used to deliver SBRT to larger tumors and to deliver IMRT with more protracted regimens as necessary. The use of a gantry system could decrease the number of LINACs that any one department requires, occupy less clinic space, and require less maintenance. Therefore, changing to an SBRT-treatment regimen may decrease the number of work hours and overall cost of treating each patient, especially with gantry SBRT.

**Robotic arm and gantry-SBRT efficacy**

The outcomes from several recent SBRT studies are listed in Table 2. The longest published median follow-up time for a robotic arm-based study is 6 years (72 months), though this was for a retrospective analysis. The longest follow-up for a gantry-based study was 60 months in a Phase II trial. The mean follow-up time for robotic arm-based studies and gantry-based studies is 3.7 years (44.4 months) and 4.3 years (50.7 months), respectively. Studies using robotic arm SBRT have included a total of 2,463 patients (mean 224 per study) and gantry SBRT studies 226 patients (mean 75 per study).

Freedom from BF (FFBF) rates for low-risk patients are ≥90% at up to 7 years (range 90%-100%) for either treatment modality. Most of the FFBF rates for intermediate risk are also ≥90%, but two studies with longer follow-up had lower rates (89.6% and 84% at 7 years and 5 years, respectively). The high-risk patients had more variability in their FFBF rates, with a range of 68.5%-90.8%. For this review article, the gantry-LINAC studies included only low-risk patients. Only one study using a gantry LINAC included non-low-risk prostate cancer patients; however, this study was excluded from the current review article because some of the patients were treated with tomotherapy SBRT.

There are a number of differences between SBRT studies and those of CFRT or HFRT. First, the follow-up times of gantry and robotic arm studies (mean 3.8 years) are significantly shorter than those of other randomized controlled trials (typically all >5 years). Second, from a historical perspective, there have been many more patients treated with CFRT and HFRT; therefore, these are the current standard-of-care treatment options in the NCCN guidelines. Third, most of the patients in the presented SBRT trials had low-risk disease. It will be necessary to enroll more intermediate- and high-risk patients to see if they have comparable outcomes.

All RT studies (CFRT, HFRT, SBRT) have used FFBF as the primary outcome measure. FFBF is limited, because the prostate specific antigen may be coming from a distant metastasis and not local failure. Although new imaging modalities (eg, multiparametric magnetic resonance imaging) exist to differentiate normal prostate from local recurrence, many of these are investigational. For now, the NCCN and American Society for Therapeutic Radiation Oncology have recognized SBRT as a possible treatment option for only low- and intermediate-risk prostate cancer. Ultimately, although the biochemical results of gantry and robotic arm SBRT studies appear promising, a number of issues must be addressed before SBRT can be considered a standard of care and gantry and robotic arm LINACs compared in more detail.

**Robotic arm and gantry-SBRT toxicity**

We summarize the late toxicities reported by studies with SBRT in Table 2. The most common grading...
systems used are the Radiation Therapy Oncology Group (RTOG) toxicity criteria and the Common Terminology Criteria for Adverse Events (CTCAE). RTOG/CTCAE was used in nine of ten studies on robotic arm SBRT and two of two studies on gantry SBRT that reported GI and GU toxicity rates. Some differences between the two grading systems have been recorded. For the purposes of this article, we provide toxicity rates from either grading system.

For robotic arm-based studies, the rate of late RTOG/CTCAE GU toxicity grade ≥2 ranged from 4% to 19.2%, and the rate of late RTOG/CTCAE GI toxicity grade ≥2 ranged from 0 to 12%. Serious late toxicities – RTOG/CTCAE grade ≥3 – were rare. Serious toxicity rates ranged from 0 to 6% and 0 to 5%, for GU and GI, respectively. For the two gantry studies by Madsen et al and Loblaw et al, the rates of late RTOG/CTCAE GU toxicity grade ≥2 were 5% and 20% and late RTOG/CTCAE GI toxicity grade ≥2 8% and 7.5%, respectively. There was only one patient in the gantry-SBRT studies who developed serious late toxicities: he had a history of diverticulitis and developed an anal fistula after radiation. Overall, GU and GI RTOG/CTCAE toxicity rates from either grading system.

The advantages and disadvantages of gantry and robotic arm LINACs are illustrated in Table 3. The current data suggest that gantry and robotic arm SBRT are similar in efficacy and toxicity. It is likely due to their similarities that there are no

Table 3 Comparison of gantry and robotic arm SBRT for prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>Gantry LINAC</th>
<th>Robotic arm LINAC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Radiobiology</strong></td>
<td>Takes advantage of low α/β ratio to increase therapeutic ratio</td>
<td>Takes advantage of low α/β ratio to increase therapeutic ratio</td>
</tr>
<tr>
<td><strong>Radiophysics</strong></td>
<td>Gold fiducial markers</td>
<td>Similar margins around CTV 6 MV only. Due to only a lower energy available, achieving optimal plans for obese patients (who are at higher risk of biochemical failure) may be difficult</td>
</tr>
<tr>
<td><strong>Resource allocation</strong></td>
<td>Less resource allocation than IMRT and protons</td>
<td>Less resource allocation than IMRT and protons</td>
</tr>
<tr>
<td><strong>Patient perspective</strong></td>
<td>Shorter treatment course than CFRT (~2 weeks vs ~8 weeks)</td>
<td>Shorter treatment course than CFRT (~2 weeks vs ~8 weeks)</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td>Comparable outcomes between gantry-based and robotic arm SBRT (5-year biochemical recurrence-free survival &gt;90%)</td>
<td>Comparable outcomes between gantry-based and robotic arm SBRT (5-year biochemical recurrence-free survival &gt;90%)</td>
</tr>
<tr>
<td><strong>Toxicity</strong></td>
<td>Early results comparable to well-established modalities</td>
<td>Early results comparable to well-established modalities</td>
</tr>
</tbody>
</table>
| **Radiation Therapy Oncology Group (RTOG) toxicity criteria and the Common Terminology Criteria for Adverse Events (CTCAE). RTOG/CTCAE was used in nine of ten studies on robotic arm SBRT and two of two studies on gantry SBRT that reported GI and GU toxicity rates. Some differences between the two grading systems have been recorded.** For the purposes of this article, we provide toxicity rates from either grading system.

Future direction

The advantages and disadvantages of gantry and robotic arm LINACs are illustrated in Table 3. The current data suggest that gantry and robotic arm SBRT are similar in efficacy and toxicity. It is likely due to their similarities that there are no
ongoing head-to-head trials comparing gantry and robotic arm SBRT in the treatment of prostate cancer. Nevertheless, there are several important active trials looking at SBRT for prostate cancer.

Phase III–IV studies will be necessary to show that SBRT is noninferior to CFRT. The current Phase III–IV trials looking at SBRT for organ-confined prostate cancer are listed in Table 4. The PACE trial has two parallel randomization arms that will compare SBRT to radical prostatectomy in patients who are surgical candidates and SBRT to CFRT in patients who are not surgical candidates.79

There are also several ongoing Phase II trials in addition to the Phase III–IV studies. RTOG 0938 is comparing SBRT (36.25 Gy in five fractions over 2 weeks) to HFRT (51.6 Gy delivered in 12 fractions over 2.5 weeks), with the primary outcome being quality of life.55 The multi-institutional study from the University of Michigan on radiofrequency fiducial guided gantry SBRT, delivers 37 Gy over five fractions. The PTV margins are smaller in this trial than RTOG 0938 (3 vs 3–5 mm). This study will help elucidate the toxicity and disease-control rates of gantry-based SBRT with real-time tracking and tighter PTV margins.46

Despite the encouraging preliminary results of SBRT for prostate cancer, there is still no consensus regarding the optimal dose and fractionation regimen for gantry and robotic arm SBRT. This makes it difficult to compare SBRT to more established treatment options. The maximum efficacious BED for prostate cancer is estimated to be 200 Gy,80 though most SBRT studies exceed this value (Figure 2). Moreover, an increase in BED and improvement in FFBF may not be associated with improvement in survival.81 In the robotic arm studies, the prescription dose ranges from 32 to 40 Gy given in four to five fractions. Katz and Kang, Berneitch et al, and Beckendorf et al found an increase in late GU toxicity in even relatively small changes in total dose.20,21,24,39 Similarly, the gantry studies had a wide range of total dose: 33.5–40 Gy. A study from the University of Texas Southwestern Medical Center (UTSW) and the University of Minnesota included prostate cancer patients treated to 45–50 Gy over five fractions. The UTSW study had the highest BED values when compared to the included studies (Figure 2), and one of the highest late grade ≥2 GU and GI toxicity rate at 11%.62,69,82 The heterogeneity in prescription doses and its relation to toxicity illustrates the need to find an optimal dose that would provide an acceptable toxicity profile without sacrificing disease control.

Conclusion
SBRT is an increasingly popular radiation-treatment practice that is hypothesized to improve tumor control, increase the therapeutic ratio, improve patient quality of life, and reduce resource consumption compared to CFRT. Our analysis of current clinical data suggests that robotic arm and gantry-based SBRT provide equivalent BF rates and toxicities. Studies included in this analysis were limited by a number of factors, including short follow-up, no report of change in overall or cancer-specific survival, exclusion of intermediate- and high-risk patients, and relatively small number of patients treated. Randomized controlled trials comparing SBRT to CFRT and HFRT using both technologies are underway.

Author contributions
All authors contributed to the conception and design, analysis, interpretation of data, and drafting and revision for

Table 4 Current Phase III–IV clinical trials of SBRT for prostate cancer

<table>
<thead>
<tr>
<th>Clinical trial name/identifier</th>
<th>Patients (n)</th>
<th>Phase</th>
<th>Risk groups</th>
<th>Treatments</th>
<th>RT system</th>
<th>Total dose (Gy)</th>
<th>Total fractions</th>
<th>Gy per fraction</th>
<th>Primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01584258</td>
<td>1,716</td>
<td>III</td>
<td>L, I</td>
<td>SBRT</td>
<td>CK</td>
<td>36.25</td>
<td>5</td>
<td>7.25</td>
<td>FFBF</td>
</tr>
<tr>
<td>Prostate advances in comparative evidence (PACE)</td>
<td>30</td>
<td>IV</td>
<td>L, I</td>
<td>SBRT</td>
<td>G</td>
<td>78</td>
<td>39</td>
<td>2</td>
<td>FFBF</td>
</tr>
<tr>
<td>St John’s Mercy Research Institute</td>
<td>592</td>
<td>III</td>
<td>I</td>
<td>SBRT</td>
<td>NR</td>
<td>42.7</td>
<td>7</td>
<td>6.1</td>
<td>FFBF</td>
</tr>
<tr>
<td>Scandinavian HYPO</td>
<td>50</td>
<td>IV</td>
<td>L, I</td>
<td>SBRT</td>
<td>G</td>
<td>36.25</td>
<td>5</td>
<td>7.25</td>
<td>Acute and late GI/ GU toxicity</td>
</tr>
<tr>
<td>Main Line Health</td>
<td>75</td>
<td>III</td>
<td>L, I</td>
<td>SBRT</td>
<td>GH</td>
<td>36.25</td>
<td>5</td>
<td>7.25</td>
<td>Biochemical, clinical, or biopsy failure</td>
</tr>
<tr>
<td>University of Miami</td>
<td>1,716</td>
<td>III</td>
<td>L, I</td>
<td>SBRT</td>
<td>G</td>
<td>70.2</td>
<td>26</td>
<td>2.7</td>
<td>FFBF</td>
</tr>
</tbody>
</table>

Abbreviations: CFRT, conventionally fractionated radiation therapy; CK, CyberKnife; EBRT, external-beam RT; FFBF, freedom from biochemical failure; G, gantry; GI, gastrointestinal; GU, genitourinary; H, high; HFRT, hypofractionated RT; I, intermediate; L, low; NR, not reported; RP, radical prostatectomy; RT, radiation therapy; SBRT, stereotactic body RT.
important intellectual content of the abstract and manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work. All figures were created by NGZ.

Disclosure

The authors report no conflicts of interest in this work.

References

31. Zaorsky NG, Hallman MA, Smallbone MC. Radiation therapy to the primary tumor in locally advanced prostate cancer is not “closing the barn door after the horse has bolted”. Ann Transl Med. 2015;3(18):274.


Supplementary materials

![PRISMA flow diagram of literature-selection process.](image)

Abbreviations: FU, follow-up; HDR-BT, high-dose-rate brachytherapy; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SBRT, stereotactic body radiation therapy

**Table S1** PICOS approach and inclusion criteria

<table>
<thead>
<tr>
<th>Population</th>
<th>Men with localized (T1–T2, N0–Nx, M0) and locally advanced (T3–T4, N0–Nx, M0) prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>SBRT monotherapy, defined as a single 6–15 Gy fraction lasting up to 45 minutes per day, for a total of up to five treatments, over approximately 2 weeks, either on a robotic arm or a gantry LINAC</td>
</tr>
<tr>
<td>Control</td>
<td>Either no control group (ie, single-arm study) or a multiarm study that may also contain the intervention</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Clinical (surrogate outcomes) for all studies: PSA kinetics, FFBF as defined by ASTRO or Phoenix definitions</td>
</tr>
<tr>
<td>Safety</td>
<td>Late RTOG or CTCAE GU, GI toxicities</td>
</tr>
<tr>
<td>Study design</td>
<td>All prospective and retrospective studies, ≥25 patients, with one or more arms, &gt;30-month FU</td>
</tr>
</tbody>
</table>

Abbreviations: ASTRO, American Society of Therapeutic Radiology and Oncology; CTCAE, Common Terminology Criteria for Adverse Events; FFBF, freedom from biochemical failure; FU, follow-up; GI, gastrointestinal; GU, genitourinary; LINAC, linear accelerator; PICOS, population, intervention, control, outcome, study design; PSA, prostate-specific antigen; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy.